NSNatalia A. Sharafutdinova

Natalia A. Sharafutdinova

*This is an algorithmically generated author record based on publicly available information.

Natalia A. Sharafutdinova has a total of 24 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • De-escalation of neoadjuvant chemotherapy in resectable oral squamous cell carcinoma: results of a comparative analysis of DC and DCF modes

    by S. I. Musin, K. V. Menshikov, A. V. Sultanbaev, I. A. Sharifgaleev, T. R. Baimuratov, N. A. Sharafutdinova, M. R. Shafikova, E. V. Tiulcov, S. V. Vtorushin, E. L. Choynzonov

    Introduction. The three-drug regimen consisting of docetaxel, cisplatin, and 5-fluorouracil (DCF) has traditionally been regarded as one of the most active neoadjuvant chemotherapy regimens for locally advanced head and neck squamous cell carcinoma. However, its use is associated with a high incidence of treatment-related adverse events. Therefore, the two-drug regimen of docetaxel plus cisplatin (DC) may represent a potential treatment de-escalation strategy for patients with initially resectable oral squamous cell carcinoma. Aim. To compare the short-term antitumor efficacy and toxicity profile of two- versus three-drug taxane-platinum neoadjuvant chemotherapy regimens in patients with resectable locally advanced oral squamous cell carcinoma. Materials and methods. This single-center retrospective cohort study included 45 patients with resectable locally advanced oral squamous cell carcinoma who received neoadjuvant chemotherapy followed by surgery between 2020 and 2026. Twenty-eight patients (62.2 %) received the DCF regimen, whereas 17 (37.8 %) received the DC regimen. Radiological response was assessed according to Response Evaluation Criteria in Solid Tumors 1.1. Pathologic response was classified as pathologic complete response, major pathologic response, or unfavorable pathologic response. Treatment-related toxicity was evaluated using the Common Terminology Criteria for Adverse Events, version 5.0. All patients received primary prophylaxis against chemotherapy-induced neutropenia with epegfilgrastim. Results. The objective response rate was 58.8 % in the DC group and 53.6 % in the DCF group (p = 0.767), whereas disease control rates were 100 and 89.3 %, respectively (p = 0.279). Tumor downstaging (reduction in T category) was observed in 64.7 and 64.3 % of patients, respectively (p = 1.000), while nodal downstaging (reduction in N category) occurred in 17.6 and 21.4 %, respectively (p = 1.000). The complete pathologic response rate was 11.8 % in the DC group and 10.7 % in the DCF group (p = 0.990), whereas the favorable pathologic response rate (complete pathologic response + major pathologic response) was 41.2 and 39.3 %, respectively (p = 1.000). R0 resection was achieved in all patients. Grade 3 adverse events occurred more frequently in the DCF group than in the DC group (53.6 % vs 17.6 %, p = 0.028), primarily because of a higher incidence of grade 3 non-hematological toxicity (42.9 % vs 5.9 %, p = 0.015). No cases of febrile neutropenia were observed. Conclusion. Among patients with resectable locally advanced oral squamous cell carcinoma, no statistically significant differences were observed between the DC and DCF regimens regarding objective response, disease control, tumor and nodal downstaging, pathologic response, or R0 resection rates. The DC regimen was associated with a significantly lower incidence of grade 3 adverse events, primarily owing to reduced non-hematological toxicity. These findings suggest that DC may represent a potential treatment de-escalation strategy for patients with initially resectable oral squamous cell carcinoma.

  • Video-Endoscopic Hemithyroidectomy via the Unilateral Axillo-Breast Approach (UABA): Results of a Single-Center Retrospective Study

    by Shamil Musin, Timerlan Baimuratov, Vasily Ilyin, Sergei Osokin, Natalya Sharafutdinova, Margarita Shafikova, Konstantin Menshikov, Alexander Sultanbaev, Marat Zamilov, Maxim Vakhitov, et al.

  • Open Access

    Effectiveness and safety of regional anesthesia techniques as an adjunct to general anesthesia in thyroidectomy: a systematic review

    by Dmitry A. Zaitсev, Shamil I. Musin, Askhat I. Karimov, Adel A. Izmailov, Sergei V. Osokin, Konstantin V. Menshikov, Alexander V. Sultanbayev, Natalia A. Sharafutdinova, Timerlan R. Baimuratov, Eduard R. Fatkulin, et al.

    Thyroidectomy is associated with moderate or intense postoperative pain and a high incidence of postoperative nausea and vomiting, along with a high need for analgesic (both opioid and non-opioid). Despite the widespread use of regional techniques (particularly cervical plexus blocks), their comparative effectiveness and safety remain insufficiently systematized; moreover, data on minimally invasive and robot-assisted approaches are limited. A systematic review was conducted in accordance with the recommendations of PRISMA-2020. The review protocol was not registered. The search was conducted in PubMed, EMBASE, ScienceDirect, Google Scholar, and eLibrary for the period from 2015 to 2025. Inclusion criteria were: randomized controlled trials, prospective and retrospective cohort studies comparing general anesthesia in combination with regional techniques (cervical plexus block, infiltration anesthesia in the surgical wound area) with a control group in adult patients undergoing elective thyroidectomy. Twenty studies were selected for qualitative synthesis. Qualitative analysis of the data demonstrated significant advantages of using combined anesthesia methods. The use of regional blocks (especially ultrasound-guided superficial cervical plexus block) in addition to general anesthesia can significantly reduce the intensity of postoperative pain during the first 24 hours; reduce the need for opioid analgesics by 1.5–3 times; reduce the frequency of postoperative nausea and vomiting by 40%–80%; and show a tendency to shorten recovery time in the ICU. The frequency of specific complications of regional methods was low ( 5%), and in some cases transient. The available data suggest that the addition of regional techniques to general anesthesia may reduce the intensity of postoperative pain, the need for opioids, and the frequency of post-thyroidectomy nausea and vomiting. However, interpretation of the results is limited by the clinical and methodological heterogeneity of the included studies, as well as the risk of bias.

  • Open Access

    Biopsy of the sentinel lymph nodes in early oral cancer: literature review

    by S. V. Osokin, Sh. I. Musin, N. A. Sharafutdinova, K. V. Menshikov, V. V. Ilyin, T. R. Baymuratov, M. R. Shafikova

    Biopsy of the sentinel lymph nodes is a modern technique of surgical staging of head and neck tumors. It allows to determine advisability of cervical lymph node dissection in patients with early-stage oral cancer. The article presents a literature review on the history, methodology, and clinical efficacy of sentinel lymph node biopsy. It is shown that technological development and implementation of new indicators increase method efficacy, minimizing unnecessary surgical interventions and decreasing the risk of complications.

  • Open Access

    Results of using revascularized flaps in patients with oral cancer after neoadjuvant chemotherapy

    by Sh. I. Musin, K. V. Menshikov, A. V. Sultanbaev, N. A. Sharafutdinov, M. M. Zamilov, R. T. Ayupov, A. F. Nasretdinov, А. О. Гузь, D. M. Fatkullin, A. N. Rudyk

    Introduction. In Russia, cancer of the oral mucosa is diagnosed in more than 9500 patients every year. In 65–70 % of cases, the disease is diagnosed at stages III–IV. Despite the use of combination treatment, prognosis in patients with stage III and IVA oral mucosa cancer remains unfavorable. Neoadjuvant chemotherapy is considered a strategy to decrease the risk of distant metastasis, decrease tumor volume, and affect the status of surgical resection margins.Aim. To evaluate the results of using revascularized flaps in patients with resectable stage III and IVA cancer of the oral mucosa who received neoadjuvant chemotherapy.Materials and methods. Retrospective analysis of data of 41 patients who underwent surgery in 2020–2023 at the Republican Clinical Oncological Dispensary (Ufa) was performed. All patients underwent R0 resection with subsequent defect reconstruction using revascularized flaps. Two groups were compared: primary patients (n = 31) and patients who received neoadjuvant therapy per the DCF (docetaxel, cisplatin, 5‑fluorouracil) (n = 10) scheme.Results. Overall rate of complications in the groups of primary patients and patients receiving neoadjuvant therapy per the DCF scheme was 16.1 and 20 %, respectively (p = 0.398), however the rate of flap loss was significantly higher in patients who underwent neoadjuvant chemotherapy: 40 % versus 9.7 % (p = 0.047). Recurrence rate in the neoadjuvant chemotherapy group was 10 %, in the group without neoadjuvant therapy it was 38.7 % (p = 0.129).Conclusion. Neoadjuvant chemotherapy can be associated with higher risk of microvascular complications and flap loss but it decreases the recurrence rate. Therefore, further search for the optimal treatment strategy for patients with cancer of the oral mucosa is necessary.